Bank Julius Baer & Co. Ltd Zurich Increases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 171,290 shares of the company's stock after purchasing an additional 3,433 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich owned about 0.21% of IDEXX Laboratories worth $95,074,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IDXX. OFI Invest Asset Management purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at about $25,000. Valley National Advisers Inc. lifted its stake in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company's stock valued at $26,000 after acquiring an additional 22 shares during the period. Geo Capital Gestora de Recursos Ltd bought a new position in IDEXX Laboratories during the 3rd quarter valued at about $28,000. Covestor Ltd lifted its stake in IDEXX Laboratories by 71.8% during the 3rd quarter. Covestor Ltd now owns 67 shares of the company's stock valued at $29,000 after acquiring an additional 28 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in IDEXX Laboratories by 108.6% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company's stock valued at $32,000 after acquiring an additional 38 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Brian P. Mckeon sold 23,326 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares of the company's stock, valued at $16,939,557.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Brian P. Mckeon sold 23,326 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the transaction, the chief financial officer now owns 29,718 shares in the company, valued at $16,939,557.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,524 shares of company stock worth $24,871,960. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $5.02 on Thursday, reaching $489.24. 358,456 shares of the stock were exchanged, compared to its average volume of 430,629. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The firm has a market capitalization of $40.63 billion, a PE ratio of 49.08, a PEG ratio of 3.80 and a beta of 1.26. The company's 50-day simple moving average is $533.74 and its two-hundred day simple moving average is $510.50. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts' consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The company had revenue of $901.60 million for the quarter, compared to analysts' expectations of $891.88 million. During the same quarter last year, the business earned $2.05 EPS. The firm's revenue was up 8.8% compared to the same quarter last year. Analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. William Blair restated an "outperform" rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Barclays upped their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Piper Sandler cut shares of IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 target price on the stock. in a research note on Tuesday, January 30th. The Goldman Sachs Group increased their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a "buy" rating in a research note on Wednesday, January 17th. Finally, JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average price target of $591.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.